# Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute

> **NIH NIH R50** · EMORY UNIVERSITY · 2023 · $156,603

## Abstract

PROJECT SUMMARY/ABSTRACT
I have devoted my career to the improvement of outcomes for patients with lymphoma and have utilized my
expertise to improve clinical trial conduct at my home institution and nationally. I have developed a sincere
commitment to the success of NCI-funded clinical trials, which often address the most critical clinical questions
and which consistently challenge the standard of care in order to improve patient outcomes nationwide. Winship
Cancer Institute of Emory University is a National Clinical Trial Network Lead Academic Participating Site and
boasts a robust clinical trial portfolio, enrolling roughly 1000 patients per year to therapeutic studies at multiple
sites throughout metropolitan Atlanta. I am the co-director of the lymphoma disease program, leader of the
lymphoma treatment modality working group, and chair of the Data Safety Monitoring Committee. In these roles
I can impact clinical trials in my clinic and throughout the Cancer Center. I have also assumed leadership of trials
through the ECOG-ACRIN lymphoma committee (PrE0404, A051201), have recently been appointed to
represent ECOG-ACRIN’s lymphoma committee on a Real World Evidence Working Group, and am the co-chair
of the lymphoma disease specific working group for Winship’s ETCTN consortium. As a result, I am well-
positioned to significantly impact of the success of NCI-funded studies. I will utilize the resources of the R50
Research Specialist Award to improve NCI-funded clinical trials through improved access and accrual to NCTN
and ETCTN trials in Atlanta and the state of Georgia by strengthening existing collaborations with oncologists
throughout the state in association with Winship’s Office of Community Outreach and Engagement. This will
include expansion of tumor boards and national programming, 1:1 in person and virtual communication with
colleagues, and facilitation of opportunities to enroll patients in NCTN studies closer to their home communities.
I will continue to develop a pipeline of junior investigators and trainees nationwide who are interested in clinical
trials and will ensure they have access to NCTN and ETCTN support to support development of their own
concepts. I will develop the next series of trials by utilizing my experience as a leader in Real World Evidence
cohorts, both within ECOG-ACRIN and with colleagues throughout the country. I will continue growth of the
NCTN and ETCTN at Winship and will ensure that colleagues continue to have innovative studies to which to
enroll patients and have the skills needed to develop their own projects based on current and future clinical
needs.

## Key facts

- **NIH application ID:** 10721093
- **Project number:** 1R50CA276010-01A1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Jonathon B. Cohen
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $156,603
- **Award type:** 1
- **Project period:** 2023-09-22 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10721093

## Citation

> US National Institutes of Health, RePORTER application 10721093, Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute (1R50CA276010-01A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10721093. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*